The company behind the BlackBerry-like Clicks Keyboard accessory for the iPhone today unveiled a new Android 16 smartphone ...

Dec 12 (Reuters) - Arcus Biosciences (RCUS.N), opens new tab said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer. Arcus ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility. The study, which was being conducted in partnership with Gilead Sciences, aimed to ...

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development program for ...

Arcus Biosciences Inc (RCUS) stock reached a significant milestone, hitting a 52-week high of 26.32 USD, representing a remarkable 304% increase from its 52-week low of 6.50 USD. According to ...

Arcus Biosciences' estimated fair value is US$41.75 based on 2 Stage Free Cash Flow to Equity Arcus Biosciences is estimated to be 39% undervalued based on current share price of US$25.56 The US$32.22 ...

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators ...

Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with ...

This content has been selected, created and edited by the Finextra editorial team based upon its relevance and interest to our community. Tapi says it has bought Arcus's utility payments, mobile ...

Wealth management technology provider Addepar acquired Arcus, a small tech startup that specializes in building out AI workflows, this week. While terms of the deal were not disclosed, Arcus’s ...